SIGA Share Price

Open 3.05 Change Price %
High 3.20 1 Day 0.13 4.26
Low 3.00 1 Week -0.07 -2.15
Close 3.18 1 Month -0.17 -5.07
Volume 65820 1 Year 2.23 234.74
52 Week High 3.88
52 Week Low 0.93
SIGA Important Levels
Resistance 2 3.37
Resistance 1 3.29
Pivot 3.13
Support 1 3.07
Support 2 2.99
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
QQQ 140.02 1.44%
DCTH 0.20 -9.09%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
SPEX 1.91 70.54%
CPSL 0.09 50.00%
LOCM 0.09 50.00%
QKLS 0.15 36.36%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SPNC 38.35 26.15%
SNTA 0.34 25.93%
OTT 2.39 25.13%
THTI 0.20 17.65%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

SIGA Technologies Inc. (NASDAQ: SIGA)

SIGA Technical Analysis 2
As on 28th Jun 2017 SIGA Share Price closed @ 3.18 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.91 & Strong Sell for SHORT-TERM with Stoploss of 3.43 we also expect STOCK to react on Following IMPORTANT LEVELS.
SIGA Target for June
1st Target up-side 3.79
2nd Target up-side 4.03
3rd Target up-side 4.27
1st Target down-side 3.11
2nd Target down-side 2.87
3rd Target down-side 2.63
SIGA Other Details
Segment EQ
Market Capital 152333136.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.siga.com
SIGA Address
SIGA
660 Madison Avenue
Suite 1700
New York, NY 10065
United States
Phone: 212-672-9100
Fax: 212-697-3130
SIGA Latest News
Interactive Technical Analysis Chart SIGA Technologies Inc. ( SIGA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on SIGA Technologies Inc.
SIGA Business Profile
SIGA Technologies, Inc. (SIGA) is a pharmaceutical company specializing in the development and commercialization of pharmaceutical solutions for some of the lethal disease-causing pathogens in the world - smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Its business is to discover, develop, manufacture and successfully commercialize drugs to prevent and treat these high-priority threats. The Company's focuses to disarm dreaded viral diseases and create robust, modern biodefense countermeasures. The Company�s product include ST-246, is an orally administered antiviral drug that targets orthopoxviruses. The Company�s lead product, ST-246, is an orally administered antiviral drug that targets orthopoxviruses. On May 13, 2011, it signed the BARDA Contract pursuant to which it agreed to deliver two million courses of ST-246 to the Strategic Stockpile.